Expand MBX Menu
MBX MENU

MBX Latest Press Releases

-- August 6, 2026 --

MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights Globe Newswire 8:00 AM

-- July 15, 2026 --

Attovia Therapeutics Appoints John W. Smither to Board of Directors Globe Newswire 8:30 AM

-- July 13, 2026 --

MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth Globe Newswire 4:15 PM

-- June 12, 2026 --

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism Globe Newswire 7:00 AM

-- June 1, 2026 --

MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026 Globe Newswire 8:00 AM

-- May 26, 2026 --

MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City Globe Newswire 8:00 AM

-- May 11, 2026 --

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing Globe Newswire 7:00 AM

-- May 7, 2026 --

MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights Globe Newswire 8:00 AM
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award Globe Newswire 7:00 AM

-- April 23, 2026 --

MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio Globe Newswire 8:00 AM

-- April 3, 2026 --

MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:00 AM

-- March 12, 2026 --

MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights Globe Newswire 8:00 AM

-- March 10, 2026 --

MBX Biosciences Appoints Karen Basbaum as Chief Business Officer Globe Newswire 8:00 AM

-- March 9, 2026 --

CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism Globe Newswire 10:21 AM
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes